+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 186 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1244801

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $51.9 Billion by 2030

The global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$28.7 Billion in the year 2022, is projected to reach a revised size of US$51.9 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030. Stimulant, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$43 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Stimulant segment is readjusted to a revised 10.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $8.4 Billion, While China is Forecast to Grow at 7.2% CAGR

The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$8.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Select Competitors (Total 27 Featured) -

  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • ADHD Therapeutics: A Primer
  • Recent Market Activity
  • ADHD Therapeutics Market Outlook
  • Factors Driving ADHD Therapeutics Market
  • Changes in Insurance Coverage
  • Addition of Formal Guidelines
  • Low Diagnosis Threshold
  • Advancements in Field of Medicine
  • Unmet Needs
  • Launch of Pipeline Drugs
  • Factors Inhibiting ADHD Therapeutics Market
  • Side Effects Related to Use of Stimulants to Treat ADHD
  • Under-diagnosis of ADHD Condition
  • Reduced Availability of Non-Stimulants in Certain Geographies
  • Competitive Landscape
  • Major ADHD Medications Available in the Market
  • ADHD Medications Approved by FDA
  • Patent Validity for Major ADHD Drugs
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • Alcobra Ltd. (Israel)
  • Amarantus Bioscience Holdings, Inc. (US)
  • Amedra Pharmaceuticals LLC (US)
  • Curemark, LLC. (US)
  • Eli Lilly and Company (US)
  • Intellipharmaceutics International, Inc. (US)
  • Janssen Global Services, LLC (US)
  • Mallinckrodt PLC (Ireland)
  • Mylan N.V. (The Netherlands)
  • Neos Therapeutics, Inc. (US)
  • Neurovance, Inc. (US)
  • Noven Pharmaceuticals, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Supernus Pharmaceuticals, Inc. (US)
  • Tris Pharma, Inc. (US)
3. MARKET TRENDS & DRIVERS
  • Biological Psychiatry Gaining Ground
  • Social Media Drives Heightened Awareness
  • Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity
  • Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market
  • Strategic Alliances
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Non-Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 18: World 18-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
  • Table 21: World 18-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2023 & 2030
  • Table 22: World Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.

Table Information